Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition

Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition

Triple positive breast cancers overexpress both the human epidermal growth factor receptor 2 (HER2) oncogene and the hormonal receptors (HR) to estrogen and progesterone. These cancers represent a unique therapeutic challenge because of a bidirectional cross-talk between the estrogen receptor alpha...

Full description

Bibliographic Details
Main Authors:	Troy B. Schedin, Virginia F. Borges, Elena Shagisultanova
Format:	Article
Language:	English
Published:	Hindawi Limited 2018-01-01
Series:	International Journal of Breast Cancer
Online Access:	http://dx.doi.org/10.1155/2018/7835095

Similar Items

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
by: Kamal Pandey, et al.
Published: (2020-11-01)

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
by: Jennifer Y. Ge, et al.
Published: (2020-05-01)

Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
by: Navid Sobhani, et al.
Published: (2021-02-01)

Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
by: Hu Y, et al.
Published: (2021-07-01)

Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
by: Fabin Dang, et al.
Published: (2021-09-01)

Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer
by: Wu Y, et al.
Published: (2020-05-01)

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
by: Neil Portman, et al.
Published: (2020-08-01)

HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
by: Sonia Pernas, et al.
Published: (2019-03-01)

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
by: Xiuzhi Zhu, et al.
Published: (2021-04-01)

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
by: Zhen Li, et al.
Published: (2020-11-01)

CDK4/6 inhibition in breast cancer: current practice and future directions
by: Sonia Pernas, et al.
Published: (2018-07-01)

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
by: Neil A. O’Brien, et al.
Published: (2020-08-01)

CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?
by: Elisa Agostinetto
Published: (2020-12-01)

CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3Kα Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma
by: Eric Remer, et al.
Published: (2020-10-01)

Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma
by: Shuo Qie, et al.
Published: (2019-03-01)

Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer
by: Nuramalina H. Mumin, et al.
Published: (2019-01-01)

Targeting WEE1 Inhibits Growth of Breast Cancer Cells That Are Resistant to Endocrine Therapy and CDK4/6 Inhibitors
by: Yassi Fallah, et al.
Published: (2021-07-01)

The emerging role of CDK4/6i in HER2-positive breast cancer
by: Ciara C. O’Sullivan, et al.
Published: (2019-11-01)

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
by: Carla L. Alves, et al.
Published: (2021-08-01)

Role of SMC1 in overcoming drug resistance in triple negative breast cancer.
by: Sushma Yadav, et al.
Published: (2013-01-01)

FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
by: Silvana Mouron, et al.
Published: (2021-02-01)

CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
by: Wang, Yubao, et al.
Published: (2017)

Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 Inhibition
by: Jingyu Peng, et al.
Published: (2021-05-01)

Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives
by: Alessandra Dall’Acqua, et al.
Published: (2021-06-01)

Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer
by: Kase AM, et al.
Published: (2020-10-01)

Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer
by: Ozge Saatci, et al.
Published: (2020-05-01)

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
by: Carla L. Alves, et al.
Published: (2021-09-01)

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
by: Luigi Formisano, et al.
Published: (2019-03-01)

Role of CDK4/CDK6 inhibitors: Ribociclib, Palbocilcib and Abemacilcib in treatment of metastatic breast cancer
by: Ghobadpour, Nazanin
Published: (2021)

LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer
by: Xi Jin, et al.
Published: (2020-05-01)

The role of CDK4/6 inhibitors in early breast cancer
by: Miguel Gil-Gil, et al.
Published: (2021-08-01)

CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge
by: Debora de Melo Gagliato, et al.
Published: (2020-09-01)

Overexpression of miRNA-3613-3p Enhances the Sensitivity of Triple Negative Breast Cancer to CDK4/6 Inhibitor Palbociclib
by: Yuanhang Yu, et al.
Published: (2020-11-01)

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
by: Lindsey R. Pack, et al.
Published: (2021-06-01)

Pharmacogenomic and High-Throughput Data Analysis to Overcome Triple Negative Breast Cancers Drug Resistance
by: Sadacca, Benjamin
Published: (2017)

Inhibiting p90 ribosomal S6 kinase (RSK)/Y-box binding protein-1 (YB-1) signaling is a novel targeted therapeutic strategy with the ability to overcome drug resistance in triple-negative breast cancer
by: Reipas, Kristen May
Published: (2013)

Inhibiting p90 ribosomal S6 kinase (RSK)/Y-box binding protein-1 (YB-1) signaling is a novel targeted therapeutic strategy with the ability to overcome drug resistance in triple-negative breast cancer
by: Reipas, Kristen May
Published: (2013)

Inhibiting p90 ribosomal S6 kinase (RSK)/Y-box binding protein-1 (YB-1) signaling is a novel targeted therapeutic strategy with the ability to overcome drug resistance in triple-negative breast cancer
by: Reipas, Kristen May
Published: (2013)

Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer
by: Qingfei Wang, et al.
Published: (2019-08-01)

Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
by: Olga Martínez-Sáez, et al.
Published: (2021-02-01)

Cannot write session to /tmp/vufind_sessions/sess_l9ncs6j9opg3troiockvl85rei